Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...

New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...

If you start to experience symptoms like chest pain, blue lips, or coughing up more than a teaspoon of blood, you should see ...

UCSF researchers shed light on how cells under stress can change their identity in harmful ways, contributing to pulmonary ...

The FDA granted approval to nerandomilast, now Jascayd, for treating adults with idiopathic pulmonary fibrosis, marking the ...

Discover groundbreaking research on pulmonary fibrosis and a potential new treatment target that could revolutionize lung ...

Avalyn will present four posters in conjunction with the PFF Summit 2025 Welcome Reception from 5-8 p.m. CT on Thursday, November 13, 2025.

The FDA has approved Boehringer Ingelheim’s Jascayd (nerandomilast) as an oral treatment option for idiopathic pulmonary fibrosis (IPF) in adult patients.

Respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) are on the rise partly because of ...